Go or no go? Covid-19 upstages US regulatory decisions
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
First clinical data show biopharma the way against Covid-19
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
A Covid-19 treatment plan slowly emerges
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
On the hunt for a Covid-19 vaccine
As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.
Tiziana takes a deep breath and targets Covid-19
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Empliciti’s front-line flop underlines Darzalex’s dominance
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Biopharma’s role in tackling coronavirus
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Another preclinical thumbs-up for Sangamo’s zinc fingers
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Coronavirus stock hype proves infectious
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
